PPH vs. IDNA
PPH (VanEck Vectors Pharmaceutical ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds - PPH tracks the MVIS US Listed Pharmaceutical 25 Index while IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. Both are passively managed. Over the past 5 years, PPH returned 9.22%/yr vs -8.42%/yr for IDNA. A 0.56 correlation means they provide meaningful diversification when combined. PPH charges 0.36%/yr vs 0.47%/yr for IDNA.
Performance
PPH vs. IDNA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PPH achieves a -0.76% return, which is significantly lower than IDNA's 10.31% return.
PPH
- 1D
- 0.33%
- 1M
- -0.56%
- YTD
- -0.76%
- 6M
- 2.14%
- 1Y
- 17.87%
- 3Y*
- 12.03%
- 5Y*
- 9.22%
- 10Y*
- 7.46%
IDNA
- 1D
- 0.73%
- 1M
- -2.56%
- YTD
- 10.31%
- 6M
- 8.52%
- 1Y
- 40.87%
- 3Y*
- 6.74%
- 5Y*
- -8.42%
- 10Y*
- —
PPH vs. IDNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
PPH VanEck Vectors Pharmaceutical ETF | -0.76% | 22.00% | 8.05% | 6.95% | 2.64% | 17.79% | 5.49% | 13.03% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 10.31% | 17.26% | -0.72% | -7.63% | -42.28% | -3.98% | 54.30% | 20.83% |
Correlation
The correlation between PPH and IDNA is 0.62, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.62 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.54 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.54 |
Correlation (All Time) Calculated using the full available price history since Jun 14, 2019 | 0.56 |
The correlation between PPH and IDNA has been stable across timeframes, ranging from 0.54 to 0.62 - a consistent structural relationship.
PPH vs. IDNA - Sectors Allocation Comparison
Sectors
PPH
IDNA
Healthcare
Industrials
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
PPH
IDNA
Industrials
PPH
IDNA
Basic Materials
PPH
-
IDNA
-
Communication Services
PPH
-
IDNA
-
Consumer Cyclical
PPH
-
IDNA
-
Consumer Defensive
PPH
-
IDNA
-
Energy
PPH
-
IDNA
-
Financial Services
PPH
-
IDNA
-
Real Estate
PPH
-
IDNA
-
Technology
PPH
-
IDNA
-
Utilities
PPH
-
IDNA
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PPH vs. IDNA — Risk / Return Rank
PPH
IDNA
PPH vs. IDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for VanEck Vectors Pharmaceutical ETF (PPH) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PPH | IDNA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.64 | ||
| Sortino ratioReturn per unit of downside risk | -0.80 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.27 | -0.08 |
| Calmar ratioReturn relative to maximum drawdown | 1.67 | 3.85 | -2.18 |
| Martin ratioReturn relative to average drawdown | 3.88 | 10.98 | -7.09 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| PPH | IDNA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.04 | 1.68 | -0.64 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.61 | -0.30 | +0.91 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.44 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.30 | 0.10 | +0.20 |
Drawdowns
PPH vs. IDNA - Drawdown Comparison
The maximum PPH drawdown since its inception was -51.45%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for PPH and IDNA.
Loading charts...
Drawdown Indicators
| PPH | IDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -51.45% | -68.26% | +16.81% |
Max Drawdown (1Y)Largest decline over 1 year | -10.76% | -10.66% | -0.10% |
Max Drawdown (3Y)Largest decline over 3 years | -18.06% | -29.73% | +11.67% |
Max Drawdown (5Y)Largest decline over 5 years | -20.26% | -68.26% | +48.00% |
Max Drawdown (10Y)Largest decline over 10 years | -29.70% | — | — |
Current DrawdownCurrent decline from peak | -8.34% | -45.61% | +37.27% |
Average DrawdownAverage peak-to-trough decline | -17.31% | -36.24% | +18.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.61% | 3.73% | +0.88% |
Volatility
PPH vs. IDNA - Volatility Comparison
The current volatility for VanEck Vectors Pharmaceutical ETF (PPH) is 4.73%, while iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) has a volatility of 7.18%. This indicates that PPH experiences smaller price fluctuations and is considered to be less risky than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PPH | IDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 4.73% | 7.18% | -2.45% |
Volatility (6M)Calculated over the trailing 6-month period | 11.67% | 17.98% | -6.31% |
Volatility (1Y)Calculated over the trailing 1-year period | 17.26% | 24.48% | -7.22% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 15.07% | 28.42% | -13.35% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 16.96% | 29.53% | -12.57% |
PPH vs. IDNA - Expense Ratio Comparison
PPH has a 0.36% expense ratio, which is lower than IDNA's 0.47% expense ratio.
Dividends
PPH vs. IDNA - Dividend Comparison
PPH's dividend yield for the trailing twelve months is around 2.12%, more than IDNA's 1.07% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.07% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% |
PPH VanEck Vectors Pharmaceutical ETF | 2.12% | 1.78% | 1.98% | 2.09% | 1.55% | 1.62% | 1.66% | 1.77% | 1.97% | 1.92% | 2.43% | 1.93% |
Frequently Asked Questions
PPH and IDNA have a correlation of 0.62, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
IDNA has higher volatility (7.18%) compared to PPH (4.73%). In terms of maximum drawdown, PPH dropped -51.45% vs IDNA's -68.26%.
On 5-year performance, PPH leads with 9.22% vs -8.42% for IDNA. On fees, PPH is cheaper at 0.36% per year. On volatility, PPH has been the lower-risk option at 4.73%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, PPH has performed better with a 9.22% return vs -8.42%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
PPH is cheaper with a 0.36% expense ratio, compared with 0.47% for IDNA.
PPH has the higher dividend yield at 2.12%, compared with 1.07% for IDNA.
PPH tracks MVIS US Listed Pharmaceutical 25 Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index. They also come from different issuers: VanEck and iShares. Their fees differ too: 0.36% for PPH and 0.47% for IDNA.
IDNA currently has the higher Sharpe Ratio (1.68 vs 1.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PPH and IDNA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer